US safety concerns delay Astellas/Cardiome's Kynapid

A new clinical trial could be required for approval of [C#198600364:Astellas]/[C#199200060:Cardiome] Pharma's novel atrial fibrillation therapy Kynapid (vernakalant HCl injection) in the US, where FDAconcerns about potential cardiovascular adverse events have delayed licensing.